Globus Medical (GMED) News Today

Globus Medical, Inc. (GMED) — The stock is moving on a strong Q1 report and an upbeat FY‑2026 outlook. Management reported an EPS and revenue beat, double‑digit revenue growth and raised full‑year EPS guidance above consensus; several analysts/shops have reacted positively. Key investor takeaways are below.

• Positive Sentiment: Q1 beat — Globus delivered EPS of $1.12 vs. $0.92 consensus and revenue of $759.85M (up 27% YoY), with healthy margins and ROE, signaling strong underlying demand. GlobeNewswire: First Quarter 2026 Results
• Positive Sentiment: Raised FY‑2026 EPS guidance — Management set FY EPS at $4.70–$4.80, above the street’s ~$4.47 estimate, which supports a re‑rating vs. earlier expectations. MarketBeat: Q1 release & guidance
• Positive Sentiment: Analyst/coverage response — Zacks and other outlets flagged the upside and have upgraded/raised estimates, which can amplify buying momentum from model‑driven funds. Yahoo Finance: Upgraded Estimates & Zacks Rank
• Neutral Sentiment: Earnings call details available — Transcripts highlight management commentary on procedure volumes, product mix and margin drivers; useful for gauging sustainability but no new material red flags reported. Seeking Alpha: Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Revenue guidance roughly in line with consensus (~$3.2B), so upside for the year is mostly tied to margin expansion and execution rather than top‑line surprises. SeattlePI: Q1 Snapshot

Bottom line for investors: Q1 results and a raised EPS target are bullish catalysts that likely pushed the stock higher; watch upcoming quarterly cadence, margin progression, and whether analysts fully lift estimates. Valuation (P/E ~21.6) and execution against the new guide will influence near‑term moves.